leptin and Soft-Tissue-Neoplasms

Our objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs).. Sixty MBC patients treated with first line hormonal therapy were enrolled in this study.. Median age was 51 years (range 28-75). Median leptin level was 19400 pg/ml (1970-91900) and estradiol level 29.6 pg/ml (4.0-181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was ≥19400 pg/ml (HR = 0.38; 95% CI: 0.16-0.91).. This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.

Topics: Adult; Aged; Aromatase Inhibitors; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Estradiol; Female; Follow-Up Studies; Humans; Leptin; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Soft Tissue Neoplasms; Survival Rate; Waist-Hip Ratio